A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

Inclusion Criteria: * Written informed consent prior to study specific screening procedures; * ≥ 18 and ≤ 75 years of age,female; * Advanced recurrent or Metastatic breast cancer, comfirmed by histological analysis and/or cytology analysis. Have failed for at least two chemotherapy regimen aimed to the advanced recurrent or metastatic focus; * Adapted to receive chemotherapy; * Women diagnosed with human epidermal growth factor receptor negative(HER2-); Women diagnosed with HER2+, and unable to be treated by Anti-HER2+ targeted therapy. HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH negative for gene amplification. HER2+ is defined as +++ staining on immunohistochemistry or FISH positive for gene amplification; * Not suitable for endocrine theapy or tolerance to endocrine therapy; * Have at least one measurable site of disease according to RECIST1.1 criteria; * If chemotherapy regimens containing anthracycline-based drugs, duration from palindromia to this chemotherapy regimens is not less than 12 mounths; * ECOG performance status of 0-2, life expectancy of more than 3 mounths; * Cardiac function is almost normal(NYHA classification is Grade 1, LVEF≥ 50％); * Sexually active women of childbearing potential must use a medically acceptable form of contraception; * Adequate hepatic, renal and hematologic functions: leukocyte≥3.0×10\^9/L,neutrophils≥1.5×10\^9/L,platelets≥75×10\^9/L, hemoglobin≥90g/L, serum bilirubin≤1.5×ULN, ALT≤2.5×ULN(5×for liver metastasis),AST≤2.5×ULN(5×for liver metastasis), creatinine clearance rate≤1.5×ULN; Exclusion Criteria: * Suffering from serious internal disease, including serious heart attack, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer; * Uncontrolled brain metastases; * Pregnant or lactating women; * Mitoxantrone has been used before; * Anthracycline-based drugs was used after relapse and metastasis; * The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 360 mg/m2 and 600 mg/m2, respectively; * Less than 4 weeks from the last chemotherapy, less than 4 weeks from the last radiotherapy, less than 2 weeks from the last endocrinotherapy; Other antineoplastic drugs need to be used in this study; * History of anthracycline-based drug allergy; * History of liposome drug allergy; * Uncontrolled psychosis or uncontrolled infections disease; * Unsuited to participate in thsi study judged by investigators;